Neurocrine Biosciences
$143.18Change from previous close: +1.76%Absolute change: +$2.47
At a glance
- Revenue growth
- +21.45%
- 2025 vs 2024
- Net income growth
- +40.23%
- 2025 vs 2024
- Net margin
- 16.7%
- 2024: 14.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 959 | 815 | 806 | 795 | 688 | — |
| Cost of revenue | 23.2 | 13.8 | 17.6 | 14.0 | 10.3 | — |
| Gross profit | 936 | 801 | 788 | 781 | 677 | — |
| Selling, general and administrative | 440 | 319 | 302 | 292 | 286 | — |
| Research and development | 327 | 296 | 258 | 250 | 244 | — |
| Operating income | 153 | 186 | 228 | 239 | 146 | — |
| EBIT | 165 | 186 | 228 | 239 | 160 | — |
| EBITDA | 190 | 193 | 235 | 247 | 167 | — |
| Interest expense | 2.9 | — | — | — | 0.0 | — |
| Pre-tax income | 162 | 247 | 239 | 292 | 160 | — |
| Income tax | 17.8 | 48.9 | 85.7 | 82.3 | 52.0 | — |
| Net income | 144 | 198 | 154 | 210 | 108 | — |
| Net income to common shareholders | 144 | 198 | 154 | 210 | 108 | — |
| Basic EPS | 1.43 | 1.97 | 1.54 | 2.11 | 1.09 | — |
| Diluted EPS | 1.39 | 1.91 | 1.48 | 2.04 | 1.06 | — |
| Average shares (basic) | 101 | 101 | 99.9 | 99.4 | 99.0 | — |
| Average shares (diluted) | 104 | 103 | 104 | 103 | 101 | — |